Wellington Management Group LLP Sells 53,177 Shares of Humana Inc. $HUM

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Wellington Management Group LLP trimmed its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 2.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,517,262 shares of the insurance provider's stock after selling 53,177 shares during the quarter. Wellington Management Group LLP owned about 2.09% of Humana worth $666,068,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of Humana during the first quarter worth $34,000. Garde Capital Inc. acquired a new stake in shares of Humana during the first quarter worth $36,000. Zions Bancorporation National Association UT acquired a new stake in shares of Humana during the first quarter worth $37,000. Finally, Transce3nd LLC acquired a new stake in shares of Humana during the fourth quarter worth $38,000. 92.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HUM shares. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price for the company in a report on Thursday, May 1st. Piper Sandler dropped their price target on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research note on Thursday, July 31st. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Robert W. Baird dropped their price target on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Finally, Wells Fargo & Company dropped their price target on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $281.43.

Humana Stock Performance

Humana stock opened at $287.75 on Tuesday. The stock has a market cap of $34.61 billion, a PE ratio of 22.08, a P/E/G ratio of 1.68 and a beta of 0.44. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The business's 50-day moving average price is $243.80 and its two-hundred day moving average price is $253.20. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $382.72.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The business's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.96 earnings per share. As a group, analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.